Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

Renal Failure Clinical Trial

Official title:

A Prospective Randomized Trial of Prednisone and Tacrolimus Versus Prednisone, Tacrolimus and Mycophenolate Mofetil in Pediatric Liver Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00656266
• Other study ID #: H-15138
• Status: Terminated
• Phase: Phase 4
• Start date: November 2004
• Est. completion date: November 2005

Study information

• Verified date: March 2020
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to compare the effects of two liver transplant immunosuppression regimens on renal function. Patients receiving the standard combination of prednisone and high-dose tacrolimus, a drug with known nephrotoxicity (Arm A) will be compared to patients receiving prednisone, low-dose tacrolimus and mycophenolate mofetil (MMF) (Arm B). MMF is an immunosuppression agent that has no associated nephrotoxicity. The primary end point of the study will be renal function as measured by glomerular filtration rate (GFR). Thirty pediatric liver transplant recipients will be randomized to these two arms in a 1:1 ratio (i.e. 15 patients in each group). Secondary end points will measure patient and graft outcome and incidence of immunosuppression-related complications, including: neurotoxicity, diabetes mellitus, growth retardation, vomiting, diarrhea, gastrointestinal hemorrhage, thrombocytopenia, anemia, leukopenia, acute or chronic liver graft rejection, posttransplant lymphoproliferative disease (PTLD), viral infections, fungal infections and bacterial infections.

Description:

The objective of this study is to compare the effects of two liver transplant immunosuppression regimens on renal function. Patients receiving the standard combination of prednisone and high-dose tacrolimus, a drug with known nephrotoxicity (Arm A) will be compared to patients receiving prednisone, low-dose tacrolimus and mycophenolate mofetil (MMF) (Arm B). MMF is an immunosuppression agent that has no associated nephrotoxicity. The primary end point of the study will be renal function as measured by glomerular filtration rate (GFR). Thirty pediatric liver transplant recipients will be randomized to these two arms in a 1:1 ratio (i.e. 15 patients in each group). Secondary end points will measure patient and graft outcome and incidence of immunosuppression-related complications, including: neurotoxicity, diabetes mellitus, growth retardation, vomiting, diarrhea, gastrointestinal hemorrhage, thrombocytopenia, anemia, leukopenia, acute or chronic liver graft rejection, posttransplant lymphoproliferative disease (PTLD), viral infections, fungal infections and bacterial infections.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: November 2005
• Est. primary completion date: November 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 16 Years

Eligibility

Inclusion Criteria:

• End-stage liver disease or acute fulminant hepatic failure recalcitrant to conventional medical or surgical therapy.

• Listed as candidate for pediatric liver transplantation listed with United Network for Organ Sharing (UNOS).

• Patients must be 18 years of age or younger.

Exclusion Criteria:

• History of autoimmune disease or primary sclerosing cholangitis.

• History of end-stage renal disease, dialysis treatment or acute renal failure (not including hepatorenal syndrome).

• Patients with pretransplant renal insufficiency as determined by a glomerular filtration rate (GFR) of <80 mL/min/1.73m2 (see below).

• Patients with renal agenesis or hypoplasia, polycystic kidney disease, or hydroureter seen on pretransplant renal ultrasound.

• Patients with malignancy or previous malignancy.

• Patients with active bacterial, viral, or fungal infections.

• Patients with a pretransplant diagnosis of diabetes mellitus.

• Patients with history of previous transplant or multi-organ recipients.

• Patients with serological evidence of HIV, HBSAg or HCV.

• Patients with hereditary syndrome that causes genetic deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan or Kelley-Seegmiller syndrome.

• Patients with history of phenylketonuria.

• Females that are pregnant or breastfeeding.

• Sexually active females who are not: a) post-menopausal, or b) surgically sterile, and c) using an acceptable method of contraception (oral contraceptive, implanted devices, injection, and barrier devices are acceptable; condoms used alone are not acceptable).

• Patients with alcohol abuse, substance abuse or smoking within the previous 6 months.

• Patients or caretakers of patients with psychogenic factors that preclude therapeutic compliance.

• Inability to reach participating hospital within 2 hours of notification.

• Any conditions or any circumstance that makes it unsafe to undergo a liver transplant.

Related Conditions & MeSH terms

• End Stage Liver Disease
• End-stage Liver Disease
• Liver Diseases
• Renal Failure
• Renal Insufficiency

Intervention

Drug:
• mycophenolate mofetil
immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept

Other:
• placebo medication
medication that looks like mycophenolate mofetil

Locations

Country	Name	City	State
United States	Baylor College of Medicine	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Baylor College of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in glomerular filtration rate (GFR) two years after liver transplantation as calculated by the Schwartz formula	change in glomerular filtration rate (GFR) two years after liver transplantation as calculated by the Schwartz formula	two years